Paysign, Inc. is executing a high-growth strategy, evidenced by a 48.1% year-over-year revenue acceleration in 2026Q2, accompanied by significant operating leverage that expanded the operating margin to 24.8%. The primary risk concerns the sustainability of it...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.11+83.3% vs $0.06 | $28M+7.2% vs $26M |
Q2 2026 May 12, 2026 | $0.09+28.6% vs $0.07 | $28M+3.8% vs $27M |
Q2 2026 Mar 24, 2026 | $0.02+0.0% vs $0.02 | $23M+5.6% vs $22M |
Q4 2025 Nov 12, 2025 | $0.04+33.3% vs $0.03 | $22M+0.2% vs $22M |
BlackRock Inc. bought a new position in Paysign, Inc. (NASDAQ: PAYS) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,079,208 shares of the company's stock, valued at approximately $25,219,000. BlackRock Inc. owned about 5.51% of Paysign as of its
Paysign NASDAQ: PAYS operates in two healthcare-focused businesses: payment services for plasma donors and pharmaceutical patient-affordability programs, Chief Financial Officer Jeff Baker said during a company presentation.
Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Paysign (PAYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Benchmark PAYS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Paysign, Inc. (PAYS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.67 | $708.33M | 97.46 | 40.5% | 9.21% | 19.13% | — | |
| $2.24 | $61.82M | -24.01 | 2.97% | -1.63% | -8.2% | — | |
| $7.80 | $642.37M | 11.47 | 8.33% | 5.61% | — | — | |
| $27.57 | $1.7B | 12.53 | 10.21% | 9.8% | 13.43% | — | |
| $13.02 | $737.98M | -7.27 | 20.72% | -1.14% | -2.82% | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — |
Paysign, Inc. (PAYS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Paysign, Inc. (PAYS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
May 13, 2026·SEC
May 12, 2026·SEC
Get notified when PAYS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Paysign, Inc. (PAYS) stock FAQ — growth, dividends, profitability & financials explained
Paysign, Inc. (PAYS) reported $100.6M in revenue for fiscal year 2025. This represents a 2251% increase from $4.3M in 2010.
Paysign, Inc. (PAYS) grew revenue by 40.5% over the past year. This is strong growth.
Yes, Paysign, Inc. (PAYS) is profitable, generating $15.8M in net income for fiscal year 2025 (9.2% net margin).
Paysign, Inc. (PAYS) has a return on equity (ROE) of 19.1%. This is reasonable for most industries.
Paysign, Inc. (PAYS) generated $67.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
